Search
ProQR Therapeutics NV
PRQRAdd to Watchlist
1.810USD
+0.060+3.43%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
194.96MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.43%
5 Days
+18.30%
1 Month
+18.30%
6 Months
-9.05%
Year to Date
-10.40%
1 Year
-16.97%
Key Figures
1.740Open
1.850High
1.19MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.10%Turnover Ratio
1.750Prev. Close
1.690Low
1.50MTurnover
LossP/E Static
3.43P/B
0.00%Div Yield TTM
-36.29%ROA
3.10052wk High
1.16Volume Ratio
-27.76MNet Profit
107.71MShares
-0.3738EPS TTM
0.07Beta
-78.07%ROE
1.33052wk Low
9.14%Amplitude
100.00%Gross Margin
194.96MMarket Cap
3.05Reward/Risk
4.71%Risk Rate
TradingKey Stock Score of ProQR Therapeutics NV
Currency: USD Updated: 2026-07-02Key Insights
ProQR Therapeutics NV's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 132 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ProQR Therapeutics NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
ProQR Therapeutics NV Highlights
StrengthsRisks
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.22% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.82M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 18.82M.
Fairly Valued
The company’s latest PE is -4.84, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 38.34M shares, decreasing 12.89% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 782.05K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.95.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.000
Target Price
+414.29%
Upside Space
ProQR Therapeutics NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ProQR Therapeutics NV Info
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Ticker SymbolPRQR
CompanyProQR Therapeutics NV
CEOde Boer (Daniel Anton)
Websitehttps://www.proqr.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of ProQR Therapeutics NV (PRQR)?
The current price of ProQR Therapeutics NV (PRQR) is 1.81.
What is the symbol of ProQR Therapeutics NV?
The ticker symbol of ProQR Therapeutics NV is PRQR.
What is the 52-week high of ProQR Therapeutics NV?
The 52-week high of ProQR Therapeutics NV is 3.10.
What is the 52-week low of ProQR Therapeutics NV?
The 52-week low of ProQR Therapeutics NV is 1.33.
What is the market capitalization of ProQR Therapeutics NV?
The market capitalization of ProQR Therapeutics NV is 194.96M.
Is ProQR Therapeutics NV (PRQR) currently rated as Buy, Hold, or Sell?
According to analysts, ProQR Therapeutics NV (PRQR) has an overall rating of Buy, with a price target of 9.00.
What is the Earnings Per Share (EPS TTM) of ProQR Therapeutics NV (PRQR)?
The Earnings Per Share (EPS TTM) of ProQR Therapeutics NV (PRQR) is -0.47.